Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosutinib versus Imatinib in Newly Diagnosed Chronic Phase CML
2013-005101-31Phase 3Completed
- Sponsor
- Pfizer
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bosutinib in chronic myelogenous leukemia (CML) (2 arms), sponsored by Pfizer. Primary endpoint: Major Molecular Response at 12 Months. Started Feb 2014; status: completed.
02
Drugs
bosutinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2013-005101-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005101-31.